Literature DB >> 3535543

Efficacy of clonidine in 24 patients with acute mania.

M C Hardy, Y Lecrubier, D Widlöcher.   

Abstract

The authors treated 24 newly hospitalized patients suffering from acute mania with 450-900 micrograms/day of clonidine, an alpha 2-adrenergic agonist, for 2 weeks. A marked decrease in manic symptoms was observed after 5 and 13 days of treatment in about half of the patients. Early response seemed to predict the final result. Patients with a family history of affective disorder and patients who had had a good response to neuroleptics during a previous manic episode tended not to respond to clonidine. At the doses given, the patients' tolerance to clonidine was excellent: sedation was markedly lower than it is with neuroleptic treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3535543     DOI: 10.1176/ajp.143.11.1450

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  5 in total

Review 1.  [Use of certain cardiological drugs in the treatment of schizophrenia: review of the literature].

Authors:  P M Llorca; M A Wolf
Journal:  J Psychiatry Neurosci       Date:  1991-03       Impact factor: 6.186

Review 2.  Investigating the mechanism(s) underlying switching between states in bipolar disorder.

Authors:  Jared W Young; Davide Dulcis
Journal:  Eur J Pharmacol       Date:  2015-03-23       Impact factor: 4.432

Review 3.  The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: a 20-year review of its use as an outcome measure.

Authors:  Per Bech
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

4.  Effects of neuroleptic drugs, clonidine and lithium on the expression of conditioned behavioral excitation in rats.

Authors:  M Poncelet; L Dangoumau; P Soubrié; P Simon
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 5.  Is Mania the Hypertension of the Mood? Discussion of A Hypothesis.

Authors:  Zoltán Rihmer; Xénia Gonda; Péter Döme
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.